{"id":799686,"date":"2026-04-01T17:23:01","date_gmt":"2026-04-01T17:23:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=799686"},"modified":"2026-04-01T17:23:01","modified_gmt":"2026-04-01T17:23:01","slug":"precision-diagnostics-medicine-market-to-reach-usd-24666-billion-by-2029","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/precision-diagnostics-medicine-market-to-reach-usd-24666-billion-by-2029_799686.html","title":{"rendered":"Precision Diagnostics & Medicine Market to Reach USD 246.66 Billion by 2029"},"content":{"rendered":"
\n
\"Precision<\/a><\/div>\n
\n
Global Precision Diagnostics and Medicine Market Ecosystem Analysis <\/div>\n<\/div>\n<\/div>\n
Driven by AI Integration and Rising Demand for Personalized Healthcare<\/div>\n

The global Precision Diagnostics & Medicine Market<\/a> is poised for significant growth, projected to expand from USD 145.53 billion in 2024 to USD 246.66 billion by 2029, registering a robust CAGR of 11.1% during the forecast period. This growth is primarily fueled by the increasing integration of artificial intelligence (AI) and machine learning (ML) in developing advanced diagnostic and therapeutic solutions. Additionally, growing collaborations and investments by leading pharmaceutical companies in precision medicine and biomarker discovery are accelerating market expansion.<\/p>\n

Download PDF Brochure:https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=215185595<\/a><\/strong><\/p>\n

The rising adoption of direct-to-consumer (DTC) testing is further supporting market growth, as patients become more proactive about their health and seek convenient, accessible diagnostic options. Moreover, pharmaceutical companies are expanding their focus beyond oncology into areas such as neurodegenerative and autoimmune diseases, creating new growth avenues. The integration of wearable technologies into healthcare ecosystems is also enhancing real-time monitoring and personalized treatment approaches, further strengthening the market outlook. However, high costs associated with precision healthcare and challenges related to big data integration and management continue to pose constraints to market growth.<\/p>\n

According to the report, the monoclonal antibodies segment is expected to account for the largest share of the precision medicine market by product throughout the forecast period. This dominance is attributed to the growing number of approved monoclonal antibody-based precision therapies, particularly for cancer and other chronic diseases. Continued regulatory approvals and strong research focus by pharmaceutical companies are further reinforcing the segment’s leading position.<\/p>\n

In terms of diagnostic indications, the oncology segment held the largest share of the precision diagnostics market in 2023. This leadership is driven by the increasing global prevalence of cancer and the rising demand for early and accurate diagnostic solutions. Life science companies are actively investing in and collaborating on the development of advanced oncology diagnostics, a trend expected to sustain the segment’s dominance in the coming years.<\/p>\n

Regionally, North America accounted for the largest share of the precision diagnostics market in 2023, followed by Europe. Meanwhile, the Asia Pacific region is projected to witness the highest growth rate during the forecast period. This rapid growth is supported by the expansion of key diagnostic players, favorable government initiatives, and increasing awareness regarding personalized medicine approaches. Developed regions continue to lead in adoption due to higher awareness and established healthcare infrastructure, while emerging economies are gradually catching up.<\/p>\n

Request Sample Pages-https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=215185595<\/a><\/strong><\/p>\n

Key players operating in the precision diagnostics market include F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), and Guardant Health (US), among others. Prominent companies in the precision medicine market include Merck & Co., Inc. (US), Gilead Sciences (US), AstraZeneca (UK), and Novartis AG (Switzerland), all of whom are actively focusing on innovation, strategic collaborations, and portfolio expansion to strengthen their market presence.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> MarketsandMarkets\u2122 Research Private Ltd.<\/a>
Contact Person:<\/strong> Mr. Rohan Salgarkar
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 18886006441
Address:<\/strong>1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City:<\/strong> Florida
State:<\/strong> Florida
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.marketsandmarkets.com<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Global Precision Diagnostics and Medicine Market Ecosystem Analysis Driven by AI Integration and Rising Demand for Personalized Healthcare The global Precision Diagnostics & Medicine Market is poised for significant growth, projected to expand from USD 145.53 billion in 2024 to … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,403,404],"tags":[],"class_list":["post-799686","post","type-post","status-publish","format-standard","hentry","category-Business","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/799686","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=799686"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/799686\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=799686"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=799686"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=799686"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}